Jamie Smith
External Media & Financial Relations Manager
Email: jamie.smith@molnlycke.com
Phone: +4673 773 39 00
Mölnlycke, a world leading MedTech company, has secured 100% renewable electricity for all its established and new manufacturing sites and its headquarters, reaching its first near-term SBTi (Science Based Targets initiative)-validated target.
Gothenburg, Sweden. 28 January 2025. “This is a significant milestone in Mölnlycke’s commitment to halving Scope 1 and 2 greenhouse gas emissions by 2030” said Caterina Camerani, VP Sustainability at Mölnlycke. “It propels us towards our vision of building a sustainable healthcare manufacturing ecosystem.”
A major enabler in reaching the goal was signing two virtual Power Purchase Agreements (vPPAs) for the regions where the company has the highest manufacturing footprint. To cover electricity consumption for the sites in the European Union, Mölnlycke signed a long-term vPPA committing to purchasing renewable electricity generated in Mutkalampi, the largest wind farm in Finland. The three manufacturing plants in Malaysia will handle their renewable electricity needs through a similar vPPA from a newly established solar power plant in Bukit Kayu Hitam, Malaysia.
In addition, Mölnlycke continues to invest in on-site generation of solar energy with manufacturing sites in Malaysia and the UK having completed the installation of rooftop solar panels and the installation on factories in Thailand ongoing.
The remaining electricity consumption needs for the established manufacturing sites in Thailand, the UK and the US, as well as the newly established plant in the Kingdom of Saudi Arabia are met through Renewable Energy Certificates (RECs). As stated in the near-term goal validated by SBTi, Mölnlycke will continue active sourcing of renewable electricity through 2030.
For more information, please contact:
External Media & Financial Relations Manager
Email: jamie.smith@molnlycke.com
Phone: +4673 773 39 00
Gothenburg, Sweden. 21 May 2025 – Mölnlycke Health Care, a global leader in MedTech, has officially opened its new global headquarters at GoCo Health Innovation City in Gothenburg, Sweden—a major milestone in its journey to drive sustainable healthcare innovation.
Gothenburg, Sweden. 13 May, 2025. Mölnlycke’s long-term net zero greenhouse gas (GHG) emission reduction targets have been validated by the Science Based Targets initiative (SBTi), following prior validation of the company’s near-term GHG emission reduction targets.
Gothenburg, Sweden. May 02, 2025. The Wound Care Collaborative Community (WCCC) is leading a groundbreaking initiative looking to develop a standardised pre-clinical testing framework for wound dressings.
Gothenburg, Sweden. 1 April 2025. Today Mölnlycke Health Care has published its Annual report for 2024, including the sustainability report.
Mölnlycke signed an agreement to acquire P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturizing.
Mölnlycke Health Care, a world leading MedTech company, has expanded its commitment to operations in the Middle East by extending its stake from 33.3% to 60% to become majority shareholder in Tamer Mölnlycke Care - a joint venture with Tamer Group, the market leader in healthcare distribution in the Kingdom of Saudi Arabia.
On 28 April 2023, Mölnlycke entered into a new EUR 350 million multicurrency revolving credit facility. The facility has a tenor of five years with two one-year extension options and will be used as a backup for general corporate purposes. The facility is a refinancing of the existing and undrawn revolving credit facility signed in 2017.
Mölnlycke Health Care’s Wound Care business area is delighted to announce the launch of its 2025 Future Summit, an educational event bringing together healthcare professionals (HCPs) from across Europe, the Middle East, and Africa (EMEA).